Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Whitener Capital Management Inc.

Whitener Capital Management Inc. lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,451 shares of the biopharmaceutical company’s stock after selling 660 shares during the period. Gilead Sciences makes up 0.8% of Whitener Capital Management Inc.’s portfolio, making the stock its 29th biggest position. Whitener Capital Management Inc.’s holdings in Gilead Sciences were worth $1,449,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Cooper Financial Group boosted its stake in Gilead Sciences by 4.3% during the 2nd quarter. Cooper Financial Group now owns 3,604 shares of the biopharmaceutical company’s stock valued at $243,000 after acquiring an additional 149 shares during the last quarter. Lenox Wealth Management Inc. boosted its stake in Gilead Sciences by 1.8% during the 1st quarter. Lenox Wealth Management Inc. now owns 9,059 shares of the biopharmaceutical company’s stock valued at $589,000 after acquiring an additional 156 shares during the last quarter. Alpha Cubed Investments LLC boosted its stake in Gilead Sciences by 0.6% during the 2nd quarter. Alpha Cubed Investments LLC now owns 25,592 shares of the biopharmaceutical company’s stock valued at $1,729,000 after acquiring an additional 156 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its stake in Gilead Sciences by 55.9% during the 1st quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 165 shares during the last quarter. Finally, Blume Capital Management Inc. boosted its stake in Gilead Sciences by 4.8% during the 2nd quarter. Blume Capital Management Inc. now owns 3,615 shares of the biopharmaceutical company’s stock valued at $244,000 after acquiring an additional 165 shares during the last quarter. 78.87% of the stock is owned by institutional investors.

A number of research firms have commented on GILD. Goldman Sachs Group downgraded shares of Gilead Sciences from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $70.00 to $60.00 in a research note on Tuesday, May 28th. Cantor Fitzgerald set a $88.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, July 15th. Wells Fargo & Co upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $68.00 to $88.00 in a research note on Monday, July 15th. Raymond James increased their price objective on shares of Gilead Sciences from $83.00 to $86.00 and gave the company a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $85.00 price objective on shares of Gilead Sciences in a research note on Wednesday, July 31st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $82.29.

Shares of GILD stock traded up $0.27 during trading hours on Friday, reaching $63.14. The stock had a trading volume of 6,967,500 shares, compared to its average volume of 6,259,398. The company has a debt-to-equity ratio of 1.13, a current ratio of 3.76 and a quick ratio of 3.67. Gilead Sciences, Inc. has a twelve month low of $60.32 and a twelve month high of $79.61. The firm has a 50-day simple moving average of $66.16 and a 200-day simple moving average of $65.90. The firm has a market capitalization of $79.94 billion, a PE ratio of 10.27, a price-to-earnings-growth ratio of 3.00 and a beta of 1.16.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.68 by $0.14. Gilead Sciences had a net margin of 26.64% and a return on equity of 37.12%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.54 billion. During the same quarter last year, the company earned $1.91 EPS. The company’s revenue for the quarter was down 2.8% compared to the same quarter last year. On average, equities analysts anticipate that Gilead Sciences, Inc. will post 6.65 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Investors of record on Friday, September 13th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, September 12th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.99%. Gilead Sciences’s dividend payout ratio (DPR) is presently 40.98%.

In related news, EVP Brett A. Pletcher sold 7,200 shares of the stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $65.07, for a total value of $468,504.00. Following the sale, the executive vice president now owns 34,398 shares of the company’s stock, valued at approximately $2,238,277.86. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total transaction of $399,850.00. Following the completion of the sale, the executive vice president now directly owns 27,198 shares in the company, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. 0.20% of the stock is owned by company insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

See Also: What are momentum indicators and what do they show?

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.